Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02443753
Other study ID # 15-1
Secondary ID
Status Terminated
Phase N/A
First received May 11, 2015
Last updated February 9, 2016
Start date May 2015
Est. completion date July 2015

Study information

Verified date February 2016
Source GI Dynamics
Contact n/a
Is FDA regulated No
Health authority Malaysia:Medical Ethics Committee, Universiti Malaya
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety and efficacy of the EndoBarrier® SANS™ in overweight and obese subjects with type 2 diabetes. The barbless second generation device is being developed as a means to reduce the incidence of adverse events associated with the barbs of the predicate device while maintaining a similar efficacy profile as measured by changes in weight and diabetic endpoints (HbA1c, blood glucose, insulin, etc.). This first use in human will primarily evaluate preliminary safety, tolerability and efficacy of the new design. Because of the new design and its first study in human subjects, only a 3 month implant duration will be evaluated in this study.


Description:

The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.

This study will be conducted at a single clinical site in Malaysia. Approximately 16 subjects will be enrolled in two cohorts of 8 subjects. The two cohorts will be implanted one week apart with the implantation of the second cohort triggered by the absence of major technical or clinical issues (i.e. safety, tolerability) observed in the first cohort in the first seven days.


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria:

- Age > 21 years and < 65 years - male or female

- Overweight or obese individuals (BMI = 27 kg/m2 and = 40 kg/m2)

- Diagnosed with Type 2 diabetes and being treated by diet or oral agents (metformin, SU, DPP-4i, or TZD)

- Glycemic state: HbA1c at screening 7.0-10.0%.

- History of failure with non-surgical weight loss methods

- Subjects willing to comply with study requirements

- Subjects who have signed an informed consent form

Exclusion Criteria:

Diabetic subjects requiring injectable treatments (insulin, GLP-1R agonists)

- Subjects requiring anticoagulation therapy

- Subjects with iron deficiency and iron deficiency anemia

- Condition of the gastrointestinal tract, such as ulcers or inflammatory bowel disease

- Treatment represents an unreasonable risk to the subject

- Known history of acute or chronic pancreatitis

- Known history of organ failure (i.e. renal insufficiency, heart failure, fibrotic / cirrhotic liver disease, or pulmonary disease)

- Symptomatic coronary artery disease or pulmonary dysfunction

- Subjects with known symptomatic biliary disease

- Known infection at the time of implant

- Severe coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia

- Congenital or acquired anomalies of the GI tract such as atresias or stenoses

- Pregnant or has the intention of becoming pregnant in the next 6 months

- Unresolved alcohol or drug addiction

- HIV positive subjects

- Subjects with hepatitis B or C

- Currently taking the following medications within 30 days of implant:

systemic corticosteroids, drugs known to affect GI motility, prescription or over the counter weight loss medications such as Sibutramine hydrochloride monohydrate and Orlistat

- Allergy or hypersensitivity to ceftriaxone, cephalosporins, penicillin, and all equivalent antibiotics

- Any characteristics which, in the opinion of the investigator, makes the subject a poor candidate for device placement in this clinical trial

- Previous GI surgery that could affect the ability to place the liner or the function of the implant.

- Subjects unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period

- H. pylori positive subjects (Note: patients may be enrolled if they had a prior history and were successfully treated).

- Family or subject history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder

- Unable to tolerate proton pump inhibitors

- Participating in another ongoing investigational clinical trial that is ongoing or within 3 months of the implant date

- Positive stool guaiac at time of screening

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
EndoBarrier SANS
Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.

Locations

Country Name City State
Malaysia Universiti Malaya Medical Centre, Jalan universiti Kuala Lumpur

Sponsors (2)

Lead Sponsor Collaborator
GI Dynamics University of Malaya

Country where clinical trial is conducted

Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and Tolerability will be evaluated as the incidence of AEs and SAEs/UADEs. Safety will be evaluated as the incidence of AEs and SAEs/UADEs. 3 months Yes
Secondary Efficacy as measured by Change in Body weight Change in Body weight 3 months No
Secondary Efficacy as measured by Percent excess weight loss Percent excess weight loss 3 months No
Secondary Efficacy as measured by Change in HbA1c (%) Change in HbA1c (%) 3 months No
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2